Special Issue

Development and Adaptation of New and Better Pediatric Drugs

Message from the Guest Editor

The combination of incentives and requirements established in recent years by drug regulatory agencies has allowed an increase in the quality, safety, and efficacy of medicines used in Pediatrics. However, this has not been sufficient and today, more than half of children are prescribed medicines whose posology is intended for an adult and which are not authorized for children, in the absence of a dosage form suitable for them. The absence of marketed medicines that meet the therapeutic needs of newborns or young children. mainly as regards the magnitude of the dose. pharmaceutical dosage form, and acceptance of the patient, justifies the individualization of treatments at different levels of care. This Special Issue includes different alternatives for the development and adaptation of pharmacological treatments for pediatrics that come to cover therapeutic gaps because the drug does not exist with the proper dose or pharmaceutical dosage form and with the proper guarantees of quality, efficacy, and safety.

Guest Editor

Prof. Dr. José B. Fariña

Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Faculty of Pharmacy, Universidad de La Laguna, 38200 La Laguna, S/C de Tenerife, Spain

Deadline for manuscript submissions

closed (30 June 2021)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/60077

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

